Form 4: Longboard Pharmaceuticals CEO Kevin Lind's Holdings Converted to Cash Following Merger

Longboard Pharmaceuticals CEO Kevin Lind's stock holdings and options were converted to cash following the company's merger with a subsidiary of H. Lundbeck A/S.

Summary

• This SEC Form 4 filing details the changes in beneficial ownership for Kevin Robert Lind, the President and CEO of Longboard Pharmaceuticals, Inc., following the company's merger.
• The merger, completed on December 2, 2024, involved H. Lundbeck A/S acquiring Longboard through a tender offer and subsequent merger.
• As a result of the merger, Lind's common stock holdings of 363,740 shares were converted to cash at a price of $60 per share.
• Additionally, his employee stock options, including 255,377 options at $3.1232, 192,783 options at $4.2, 325,850 options at $4.35, and 332,134 options at $19.32, were also converted to cash based on the difference between the $60 merger price and the exercise price.
• Lind's 22,000 restricted stock units (RSUs) were also converted to cash, with payment subject to the original vesting schedule or involuntary termination.
• The merger agreement dictates the terms of these conversions, and any discrepancies between the form and the agreement will be resolved by the agreement.

Sentiment

Score: 7

Explanation: The document is a standard SEC filing related to a merger, indicating a positive outcome for shareholders and executives who received cash for their holdings. The sentiment is neutral to positive as it reflects the completion of a planned transaction.

Future Outlook

The document does not contain any forward-looking statements beyond the completion of the merger.

Industry Context

This document reflects a common scenario in mergers and acquisitions where executive holdings are converted to cash as part of the transaction. It is a standard procedure to ensure a clean transfer of ownership.

Comparison to Industry Standards

• The conversion of stock options and restricted stock units to cash upon a merger is a standard practice in the pharmaceutical industry.
• The $60 per share cash consideration is typical in acquisitions of this nature, where a premium is paid over the pre-merger stock price.
• Similar transactions can be seen in the acquisitions of other biotech companies, such as the acquisition of Immunomedics by Gilead Sciences, where stock options and RSUs were also converted to cash.

Stakeholder Impact

• Shareholders received $60 per share in cash.
• Employees with stock options and RSUs received cash based on the merger terms.
• The company is now a subsidiary of H. Lundbeck A/S.

Key Dates

Keywords

Merger, Acquisition, Longboard Pharmaceuticals, H. Lundbeck A/S, SEC Form 4, Beneficial Ownership, Stock Options, Restricted Stock Units, Kevin Lind